Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Markman

Showing results (351-360 of 545) with videos related to

Pageof 55
Sort By:
Gynecologic Oncology|June 15, 1999
Persistent chemosensitivity to platinum and/or paclitaxel in metastatic endometrial cancerM Markman, A Kennedy, K Webster, et al.
Journal of Cancer Research and Clinical Oncology|May 18, 2000
Experience with prophylactic oral ciprofloxacin in gynecological cancer patients developing severe chemotherapy-induced neutropeniaM Markman, A Kennedy, K Webster, et al.
Gynecologic Oncology|September 28, 2000
Phase 2 evaluation of topotecan administered on a 3-day schedule in the treatment of platinum- and paclitaxel-refractory ovarian cancerM Markman, A Kennedy, K Webster, et al.
Gynecologic Oncology|September 14, 2000
Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneumM Markman, A Kennedy, K Webster, et al.
Gynecologic Oncology|April 29, 2000
Declining CA-125 in an ovarian cancer patient with progression of measurable disease: a rational hypothesis for discordant resultsM Markman, A Kennedy, K Webster, et al.
Gynecologic Oncology|June 1, 1997
Continued chemosensitivity to cisplatin/carboplatin in ovarian carcinoma despite treatment with multiple prior platinum-based regimensM Markman, A Kennedy, K Webster, et al.
Journal of Cancer Research and Clinical Oncology|July 8, 1999
An effective and more convenient drug regimen for prophylaxis against paclitaxel-associated hypersensitivity reactionsM Markman, A Kennedy, K Webster, et al.
Medical and Pediatric Oncology|January 1, 1984
Anaphylactic reaction to cytarabine: in vitro evidence that the response is immunoglobulin E mediatedM Markman, S B Howell, M King, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 1997
Simplified regimen for the prevention of paclitaxel-associated hypersensitivity reactionsM Markman, A Kennedy, K Webster, et al.
Seminars in Oncology|November 5, 1997
Carboplatin plus paclitaxel in the treatment of gynecologic malignancies: the Cleveland Clinic experienceM Markman, A Kennedy, K Webster, et al.
Pageof 55

Showing results (351-360 of 545) with videos related to

Sort By:
Pageof 55
Gynecologic Oncology|June 15, 1999
Persistent chemosensitivity to platinum and/or paclitaxel in metastatic endometrial cancerM Markman, A Kennedy, K Webster, et al.
Journal of Cancer Research and Clinical Oncology|May 18, 2000
Experience with prophylactic oral ciprofloxacin in gynecological cancer patients developing severe chemotherapy-induced neutropeniaM Markman, A Kennedy, K Webster, et al.
Gynecologic Oncology|September 28, 2000
Phase 2 evaluation of topotecan administered on a 3-day schedule in the treatment of platinum- and paclitaxel-refractory ovarian cancerM Markman, A Kennedy, K Webster, et al.
Gynecologic Oncology|September 14, 2000
Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneumM Markman, A Kennedy, K Webster, et al.
Gynecologic Oncology|April 29, 2000
Declining CA-125 in an ovarian cancer patient with progression of measurable disease: a rational hypothesis for discordant resultsM Markman, A Kennedy, K Webster, et al.
Gynecologic Oncology|June 1, 1997
Continued chemosensitivity to cisplatin/carboplatin in ovarian carcinoma despite treatment with multiple prior platinum-based regimensM Markman, A Kennedy, K Webster, et al.
Journal of Cancer Research and Clinical Oncology|July 8, 1999
An effective and more convenient drug regimen for prophylaxis against paclitaxel-associated hypersensitivity reactionsM Markman, A Kennedy, K Webster, et al.
Medical and Pediatric Oncology|January 1, 1984
Anaphylactic reaction to cytarabine: in vitro evidence that the response is immunoglobulin E mediatedM Markman, S B Howell, M King, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 1997
Simplified regimen for the prevention of paclitaxel-associated hypersensitivity reactionsM Markman, A Kennedy, K Webster, et al.
Seminars in Oncology|November 5, 1997
Carboplatin plus paclitaxel in the treatment of gynecologic malignancies: the Cleveland Clinic experienceM Markman, A Kennedy, K Webster, et al.
Pageof 55